Skip to main content

UNITED THERAPEUTICS Corp 10-Q for FY2026 Q3

UNITED THERAPEUTICS Corp (UTHR)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

UNITED THERAPEUTICS Corp filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

United Therapeutics said Liquidia must remove PH-ILD from Yutrepia’s label after an adverse patent ruling and agreed to pay $330.4 million for past and future damages; Nebulized Tyvaso’s IPF application has an FDA goal date of April 26, 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$832.5M
up 4.1% from $799.5M a year earlier
Net income
$258.6M
down 23.6% from net income of $338.7M a year earlier
Diluted EPS
$5.71
down 20.3% from $7.16 a year earlier